



**Vivimed**

Date:10/11/2015

To

BSE Limited  
Listing Department  
P.J.Towers, Dalal Street,  
Mumbai – 400001

**BSE - Scripe Code : 532660**

National Stock Exchange of India Ltd  
Listing Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra(E),Mumbai – 400051

**NSE- Symbol: VIVIMEDLAB**

Dear Sir/Madam

**Sub: Outcome of the Meeting of the Board of Directors of the Company – reg**

The Board of Directors of the Company at its meeting held on November 10, 2015, inter alia, have approved/resolved/taken note of the following:

1. Pursuant to clause 41 of Listing Agreement entered into with the stock exchanges, considered and approved the submission of the Un audited Financial Results (Standalone & Consolidated) for the Quarter & half year ended September 30,2015 attached herewith;
2. The Board took note of Auditor's Limited Review Report on the un Audited Financial Statements of the Company for the Quarter & half year ended September 30,2015

An earnings related presentation including business highlights will be uploaded on the company's website [www.vivimedlabs.com](http://www.vivimedlabs.com)

You are requested to take note of the above.

Yours faithfully

**For VIVIMED LABS LTD**

  
**SANTOSH VARALWAR**  
**MANAGING DIRECTOR & CEO**




**VIVIMED LABS LIMITED**  
**UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30<sup>th</sup> SEP 2015**

Sl. No.	Particulars	Quarter Ended				Half Year Ended		Previous Year ended 31.03.2015
		30.09.2015	30.06.2015	30.09.2014	30.09.2015	30.09.2014	(Audited)	
<b>1</b>	<b>Income From Operations</b>	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
	(a) Net Sales / Income from Operations (Net of Excise Duty)	33,702.81	33,152.85	31,363.86	66,855.65	68,017.51	1,38,009.91	
	(b) Other Operating Income	452.10	143.60	315.71	595.70	438.20	586.57	
	<b>Total Income From Operations (Net)</b>	<b>34,154.91</b>	<b>33,296.44</b>	<b>31,679.58</b>	<b>67,451.35</b>	<b>68,455.71</b>	<b>1,38,596.49</b>	
	a. Cost of Raw Materials Consumed	15,448.89	15,372.70	16,718.48	30,821.59	35,479.96	69,931.61	
	b. Purchase of Stock in Trade	-	-	-	-	-	-	
	c. Changes in Inventories of finished Goods, Work-in-Progress and Stock in Trade	497.50	(553.92)	(1,917.53)	(56.42)	(3,366.85)	(5,309.20)	
	d. Employee Benefit Expenses	3,776.21	4,543.03	4,225.10	8,319.24	8,941.49	18,442.79	
	e. Depreciation and Amortisation Expenses	1,638.86	1,478.38	1,633.82	3,117.24	3,303.97	6,617.76	
	f. Other Expenditure	8,114.71	7,212.42	7,474.68	15,327.13	16,415.40	33,256.12	
<b>2</b>	<b>Total Expenses</b>	<b>29,476.17</b>	<b>28,052.61</b>	<b>28,154.54</b>	<b>57,528.79</b>	<b>60,773.97</b>	<b>1,22,939.08</b>	
<b>3</b>	<b>Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)</b>	<b>4,678.74</b>	<b>5,243.83</b>	<b>3,525.04</b>	<b>9,922.56</b>	<b>7,681.74</b>	<b>15,657.41</b>	
<b>4</b>	Other Income	-	-	-	-	-	-	
<b>5</b>	<b>Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)</b>	<b>4,678.74</b>	<b>5,243.83</b>	<b>3,525.04</b>	<b>9,922.56</b>	<b>7,681.74</b>	<b>15,657.41</b>	
<b>6</b>	Finance Costs	1,879.61	1,904.50	1,968.75	3,784.12	3,809.17	7,903.68	
<b>7</b>	<b>Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)</b>	<b>2,799.12</b>	<b>3,339.33</b>	<b>1,556.29</b>	<b>6,138.44</b>	<b>3,872.57</b>	<b>7,753.73</b>	
<b>8</b>	Exceptional items	-	-	-	-	-	-	
<b>9</b>	<b>Profit / Loss from ordinary activities before Tax (7 - 8)</b>	<b>2,799.12</b>	<b>3,339.33</b>	<b>1,556.29</b>	<b>6,138.44</b>	<b>3,872.57</b>	<b>7,753.73</b>	
<b>10</b>	Tax Expenses	411.53	921.98	(84.79)	1,333.51	518.45	548.69	
<b>11</b>	<b>Net Profit / Loss from ordinary activities after Tax (9 - 10)</b>	<b>2,387.59</b>	<b>2,417.35</b>	<b>1,641.08</b>	<b>4,804.94</b>	<b>3,354.12</b>	<b>7,205.04</b>	
<b>12</b>	Extraordinary Items (net of tax expenses Rs.....lacs)	-	-	-	-	-	-	
<b>13</b>	<b>Net Profit / Loss for period (11 - 12)</b>	<b>2,387.59</b>	<b>2,417.35</b>	<b>1,641.08</b>	<b>4,804.94</b>	<b>3,354.12</b>	<b>7,205.04</b>	
<b>14</b>	Share of Profit / (Loss) of associates	-	-	-	-	-	-	
<b>15</b>	Minority Interest	-	-	-	-	-	-	
<b>16</b>	<b>Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)</b>	<b>2,387.59</b>	<b>2,417.35</b>	<b>1,641.08</b>	<b>4,804.94</b>	<b>3,354.12</b>	<b>7,205.04</b>	
<b>17</b>	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	
<b>18</b>	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	-	-	-	-	-	-	
<b>19</b>	Earnings per Share (before Extraordinary Items) (of Rs...../- each) (not annualised)	(a) Basic 14.73	14.92	10.13	29.65	20.70	44.47	
	(b) Diluted	14.73	14.92	10.13	29.65	20.70	44.47	

- The above Consolidated Unaudited Financial Results for the Quarter & Half year ended SEPTEMBER 30<sup>TH</sup> 2015 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 10<sup>th</sup> NOVEMBER 2015
- Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Klar Sehen Private Limited, (iv) Octantis Nobel Labs Private Limited, (v) Vivimed Labs (Alathur) Pvt Limited (vi) Finoso Pharma Pvt Limited (vii) Vivimed specialty chemicals Pvt Ltd and its step down subsidiaries viz. (viii) Vivimed Holdings Limited and its stepdown subsidiary Vivimed Labs Europe Limited (ix) Vivimed Labs Mauritius Limited and its stepdown subsidiaries (i) Vivimed Labs UK Limited, (ii) Vivimed Labs Spain, S.L. (iii) Union Quimico Farmaceutica S.A.U., Spain, (iv) Holiday International Limited, UK & (v) Uquifa Mexico S.A. de C.V.
- The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.
- The company has calculated depreciation as per the provisions under Companies Act of 2013.
- VIVIMED LABS LTD. has entered into a binding Agreement with CLARIANT INDIA LTD. to sell part of its Specialty Chemicals business. The Business Transfer Agreement (BTA) was entered between the two Companies on 29<sup>th</sup> Sep. '15. Under this BTA, the consideration receivable is Rs. 380 Crs.

Place : Hyderabad  
Date : 10.11.2015

For VIVIMED LABS LIMITED  
(SANTOSH VARALWAR)  
MANAGING DIRECTOR & CEO



**VIVIMED LABS LIMITED**

**SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT**

Rs in Lacs

Particulars	3 Months Ended			Half Year Ended		FY 15 31-03-2015 (Audited)
	30.09.2015 (Unaudited)	30.06.2015 (Unaudited)	30.09.2014 (Unaudited)	30.09.2015 (Unaudited)	30.09.2014 (Unaudited)	
<b>1. Segment Revenue</b> (net sales/income from each segment should be disclosed under this head)						
a. Speciality Chemicals Business	9,430.16	9,575.42	9,866.70	19,005.58	18,728.36	44,620.88
b. Pharma Business	24,272.64	23,577.43	21,497.16	47,850.07	49,289.15	93,389.04
<b>Total</b>	<b>33,702.81</b>	<b>33,152.85</b>	<b>31,363.86</b>	<b>66,855.65</b>	<b>68,017.51</b>	<b>1,38,009.92</b>
Less, Inter Segment Revenue				-		
<b>Net sales / Income from Operations</b>	<b>33,702.81</b>	<b>33,152.85</b>	<b>31,363.86</b>	<b>66,855.65</b>	<b>68,017.51</b>	<b>1,38,009.92</b>
<b>2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>						
a. Speciality Chemicals Business	2,111.07	1,740.39	2,351.05	3,851.46	4,138.53	9,004.64
b. Pharma Business	2,567.67	3,503.44	1,173.99	6,071.10	3,543.21	6,652.77
<b>Total</b>	<b>4,678.74</b>	<b>5,243.83</b>	<b>3,525.04</b>	<b>9,922.56</b>	<b>7,681.73</b>	<b>15,657.41</b>
Less: 1. Interest	1,879.61	1,904.50	1,968.75	3,784.12	3,809.17	7,903.68
2. Other Un-allocable Expenditure						
3. Un-allocable Income						
<b>Total Profit Before Tax</b>	<b>2,799.12</b>	<b>3,339.33</b>	<b>1,556.29</b>	<b>6,138.44</b>	<b>3,872.56</b>	<b>7,753.73</b>
<b>3. Capital Employed</b>						
a. Speciality Chemicals Business	74,152.66	81,173.74	79,112.06	74,152.66	79,112.06	80,489.58
b. Pharma Business	66,437.84	68,788.00	64,002.71	66,437.84	64,002.71	68,208.23
<b>Total</b>	<b>1,40,590.51</b>	<b>1,49,961.73</b>	<b>1,43,114.77</b>	<b>1,40,590.51</b>	<b>1,43,114.77</b>	<b>1,48,697.80</b>

For VIVIMED LABS LIMITED

(SANTOSH KARALWAR)

MANAGING DIRECTOR & CEO

Place : Hyderabad

Date : 10.11.2015



**VIVIMED LABS LIMITED**  
**UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30<sup>TH</sup> SEP 2015**

Sl. No.	Particulars	Quarter Ended				Half Year Ended		Previous Year ended 31.03.2015
		30.09.2015	30.06.2015	30.09.2014	30.09.2015	30.09.2014		
<b>1</b>	<b>Income From Operations</b>	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
	(a) Net Sales / Income from Operations (Net of Excise Duty)	8,009.12	7,971.31	9,573.18	15,980.44	19,846.02	43,014.81	
	(b) Other Operating Income	17.48	12.70	40.34	30.18	38.44	143.40	
	<b>Total Income From Operations (Net)</b>	<b>8,026.61</b>	<b>7,984.01</b>	<b>9,613.52</b>	<b>16,010.62</b>	<b>19,884.46</b>	<b>43,158.21</b>	
	a. Cost of Raw Materials Consumed	2,861.20	3,455.20	5,678.17	6,316.40	12,549.88	25,110.30	
	b. Purchase of Stock in Trade	-	-	-	-	-	-	
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	394.47	(12.89)	(1,602.79)	381.58	(3,469.46)	(5,319.45)	
	d. Employee Benefit Expenses	604.85	529.77	830.03	1,134.62	1,379.61	2,788.34	
	e. Depreciation and Amortisation Expenses	412.75	484.51	451.62	897.26	899.78	2,056.04	
	f. Other Expenditure	1,973.72	1,752.94	2,190.93	3,726.66	4,371.19	9,863.94	
<b>2</b>	<b>Total Expenses</b>	<b>6,246.99</b>	<b>6,209.53</b>	<b>7,547.97</b>	<b>12,456.52</b>	<b>15,731.01</b>	<b>34,499.17</b>	
<b>3</b>	<b>Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)</b>	<b>1,779.62</b>	<b>1,774.48</b>	<b>2,065.55</b>	<b>3,554.10</b>	<b>4,153.45</b>	<b>8,659.04</b>	
<b>4</b>	<b>Other Income</b>	-	-	-	-	-	-	
<b>5</b>	<b>Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)</b>	<b>1,779.62</b>	<b>1,774.48</b>	<b>2,065.55</b>	<b>3,554.10</b>	<b>4,153.45</b>	<b>8,659.04</b>	
<b>6</b>	<b>Finance Costs</b>	1,502.14	1,492.82	1,491.92	2,994.96	2,919.52	6,233.53	
<b>7</b>	<b>Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)</b>	<b>277.48</b>	<b>281.66</b>	<b>573.63</b>	<b>559.13</b>	<b>1,233.93</b>	<b>2,425.51</b>	
<b>8</b>	<b>Exceptional items</b>	-	-	-	-	-	-	
<b>9</b>	<b>Profit / Loss from ordinary activities before Tax (7 - 8)</b>	<b>277.48</b>	<b>281.66</b>	<b>573.63</b>	<b>559.13</b>	<b>1,233.93</b>	<b>2,425.51</b>	
<b>10</b>	<b>Tax Expenses</b>	50.43	64.86	136.30	115.29	313.48	531.99	
<b>11</b>	<b>Net Profit / Loss from ordinary activities after Tax (9 - 10)</b>	<b>227.05</b>	<b>216.80</b>	<b>437.33</b>	<b>443.84</b>	<b>920.45</b>	<b>1,893.52</b>	
<b>12</b>	<b>Extraordinary items (net of tax expenses Rs.....Lacs)</b>	-	-	-	-	-	-	
<b>13</b>	<b>Net Profit / Loss for period (11 - 12)</b>	<b>227.05</b>	<b>216.80</b>	<b>437.33</b>	<b>443.84</b>	<b>920.45</b>	<b>1,893.52</b>	
<b>14</b>	<b>Share of Profit / (Loss) of associates</b>	-	-	-	-	-	-	
<b>15</b>	<b>Minority Interest</b>	-	-	-	-	-	-	
<b>16</b>	<b>Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)</b>	<b>227.05</b>	<b>216.80</b>	<b>437.33</b>	<b>443.84</b>	<b>920.45</b>	<b>1,893.52</b>	
<b>17</b>	<b>Paid up Equity Share Capital (Face value of the Share shall be indicated)</b>	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	
<b>18</b>	<b>Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year</b>	-	-	-	-	-	-	
<b>19</b>	<b>Earnings per Share (before Extraordinary Items) (of Rs...../- each) (not annualised)</b>	1.40	1.34	2.70	2.74	5.68	11.69	
	(a) Basic	1.40	1.34	2.70	2.74	5.68	11.69	
	(b) Diluted	1.40	1.34	2.70	2.74	5.68	11.69	

- The above Standalone Unaudited Financial Results for the Quarter & Half year ended SEPTEMBER 30<sup>TH</sup> 2015 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 10<sup>TH</sup> NOVEMBER 2015
- The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.
- The company has calculated depreciation as per the provisions under Companies Act of 2013.
- VIVIMED LABS LTD. has entered into a binding Agreement with CLARIANT INDIA LTD. to sell part of its Specialty Chemicals business. The Business Transfer Agreement (BTA) was entered into between the Companies on 29<sup>th</sup> Sep '15. Under this BTA, the consideration receivable is Rs 380 Crs.

Place : Hyderabad  
 Date : 10.11.2015

For VIVIMED LABS LIMITED  
 (SANTOSH NABAKWARI)  
 MANAGING DIRECTOR & CEO



**VIVIMED LABS LIMITED**  
**SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT**

Rs in Lacs

Particulars	3 Months Ended			Half Year Ended		FY 15 31-03-2015 (Audited)
	30.09.2015 (Unaudited)	30.06.2015 (Unaudited)	30.09.2014 (Unaudited)	30.09.2015 (Unaudited)	30.09.2014 (Unaudited)	
<b>1. Segment Revenue</b> (net sales/income from each segment should be disclosed under this head)						
a.Speciality Chemicals Business	5,914.68	6,066.04	7,914.34	11,980.72	15,914.03	34,941.15
b.Pharma Business	2,094.44	1,905.28	1,658.84	3,999.72	3,931.99	8,073.66
<b>Total</b>	<b>8,009.12</b>	<b>7,971.31</b>	<b>9,573.18</b>	<b>15,980.44</b>	<b>19,846.02</b>	<b>43,014.81</b>
Less, Inter Segment Revenue		-				
<b>Net sales / Income from Operations</b>	<b>8,009.12</b>	<b>7,971.31</b>	<b>9,573.18</b>	<b>15,980.44</b>	<b>19,846.02</b>	<b>43,014.81</b>
<b>2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>						
a.Speciality Chemicals Business	1,583.55	1,636.90	1,736.68	3,220.45	3,297.08	7,271.32
b.Pharma Business	196.07	137.57	328.87	333.64	856.36	1,387.72
<b>Total</b>	<b>1,779.62</b>	<b>1,774.47</b>	<b>2,065.55</b>	<b>3,554.10</b>	<b>4,153.45</b>	<b>8,659.04</b>
Less: 1.Interest	1,502.14	1,492.82	1,491.92	2,994.96	2,919.52	6,233.53
2.Other Un-allocable Expenditure		-				
3.Un-allocable Income		-				
<b>Total Profit Before Tax</b>	<b>277.48</b>	<b>281.66</b>	<b>573.63</b>	<b>559.13</b>	<b>1,233.92</b>	<b>2,425.51</b>
<b>3. Capital Employed</b>						
a.Speciality Chemicals Business	79,173.69	81,955.60	76,294.65	79,173.69	76,294.65	81,955.60
b.Pharma Business	32,244.29	31,968.95	29,108.61	32,244.29	29,108.61	31,968.95
<b>Total</b>	<b>1,11,417.99</b>	<b>1,13,924.55</b>	<b>1,05,403.27</b>	<b>1,11,417.99</b>	<b>1,05,403.26</b>	<b>1,13,924.55</b>

Place : Hyderabad  
Date : 10.11.2015

FOR VIVIMED LABS LIMITED  
(SANTOSH VARALWAR)  
MANAGING DIRECTOR & CEO



VIVIMED LABS LIMITED

UNAUDITED STANDALONE & CONSOLIDATED BALANCE SHEET AS AT SEPTEMBER'30th,2015

Rs in Lakhs



S.No	Particulars	STANDALONE		CONSOLIDATED	
		As at	As at	As at	As at
		30.09.2015 (Unaudited)	31.03.2015 (Audited)	30.09.2015 (Unaudited)	31.03.2015 (Audited)
<b>(A)</b>	<b>EQUITY AND LIABILITIES</b>				
1	Shareholders funds				
	(a) Share Capital				
	i) Equity Share Capital	1,620.38	1,620.38	1,620.38	1,620.38
	ii) Preference Share capital	-	-	6,394.56	6,394.56
	(b) Reserves and Surplus	35,004.62	35,774.58	49,278.59	47,908.55
	(c) Money Received against Share Warrants	-	-	-	-
	<b>Sub Total Shareholders Funds</b>	<b>36,625.00</b>	<b>37,394.96</b>	<b>57,293.53</b>	<b>55,923.49</b>
2	<b>Non-current liabilities</b>				
	a) Long-term borrowings	23,407.02	30,780.73	33,079.30	48,338.15
	(b) Deferred tax liabilities (net)	3,154.78	3,154.78	1,019.04	937.13
	(c) Other long-term liabilities	13,310.20	12,282.80	3,525.36	4,243.81
	(d) Long-term provisions	295.82	301.05	314.72	316.96
	<b>Sub-total - Non-current liabilities</b>	<b>40,167.82</b>	<b>46,519.36</b>	<b>37,938.43</b>	<b>53,836.05</b>
3	<b>Current liabilities</b>				
	(a) Short-term borrowings	34,625.17	29,118.86	45,358.55	38,938.26
	(b) Trade payables	1,920.36	4,560.86	18,024.38	18,871.38
	(c) Other current liabilities	16,116.96	10,166.27	31,971.15	17,637.68
	(d) Short-term provisions	3,671.05	2,515.40	6,177.17	4,638.95
	<b>Sub-total - Current liabilities</b>	<b>56,333.54</b>	<b>46,361.39</b>	<b>1,01,531.24</b>	<b>80,086.27</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>1,33,126.36</b>	<b>1,30,275.71</b>	<b>1,96,763.21</b>	<b>1,89,845.81</b>
<b>(B)</b>	<b>ASSETS</b>				
1	<b>Non-current assets</b>				
	(a) Fixed assets				
	(i) Tangible Assets	35,648.71	36,466.11	69,254.45	69,629.81
	(ii) Intangible Assets	1,129.71	1,189.17	10,127.58	11,717.24
	(iii) Capital work in progress	6,827.92	6,327.21	9,448.90	9,028.16
	(b) Non Current Investment	-	23,004.55	270.00	270.00
	(c) Long Term Loans and advances	23,004.55	-	-	-
	(d) Other Non Current Assets	-	-	4.29	4.37
	<b>Sub-total - Non-current assets</b>	<b>66,610.90</b>	<b>66,987.04</b>	<b>89,105.22</b>	<b>90,649.59</b>
2	<b>Current Assets</b>				
	(a) Inventories	27,577.45	22,249.87	50,758.32	43,143.27
	(b) Trade receivables	19,997.47	22,807.52	27,346.30	32,957.80
	(c) Cash and cash equivalents	805.08	1,399.45	2,344.16	2,667.07
	(d) Short-term loans and advances	17,542.32	16,238.69	26,248.58	18,521.29
	(e) Other current assets	593.14	593.14	960.62	1,906.78
	<b>Sub-total - Current assets</b>	<b>66,515.46</b>	<b>63,288.67</b>	<b>1,07,657.99</b>	<b>99,196.21</b>
	<b>TOTAL - ASSETS</b>	<b>1,33,126.36</b>	<b>1,30,275.71</b>	<b>1,96,763.21</b>	<b>1,89,845.81</b>



		Part II					
		Select Information for the Quarter and Half Year Ended 30/09/2015					
SL.No	Particulars	Quarter ended 30/09/2015	Quarter ended 30/06/2015	Quarter ended 30/09/2014	Half Year ended 30/09/2015	Half Year ended 30/09/2014	Year ended 31/03/2015
A	<b>PARTICULARS OF SHAREHOLDING</b>						
	<b>Public Shareholding</b>						
	Number of Shares	10210555	10210555	10026058	10210555	10026058	10059058
	Percentage of Shareholding	63.01%	63.01%	61.87%	63.01%	61.87%	62.08%
	<b>Promoter and Promoter Group Shareholding</b>						
	(a) Pledged/ Encumbered						
	Number of Shares	5248116	4998000	3110455	5248116	3110455	4823000
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	87.57%	83.39%	50.35%	87.57%	50.35%	78.49%
	Percentage of shares (as a % of the total share capital of the company)	32.39%	30.85%	19.20%	32.39%	19.20%	29.76%
	(b) Non-encumbered						
	Number of Shares	745112	995228	3067270	745112	3067270	1321725
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	12.43%	16.61%	49.65%	12.43%	49.65%	21.51%
	Percentage of shares (as a % of the total share capital of the company)	4.60%	6.14%	18.93%	4.60%	18.93%	8.16%

#### Investor's Complaints

Sl.no	Particulars	3 months ended 30/09/2015
B	Pending at the beginning of the quarter	Nil
	Received during the quarter	Nil
	Disposed of during the quarter	Nil
	Remaining unresolved at the end of the quarter	Nil



**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
2339 3967, 2332 1470  
Fax : (91-40) 2339 2474  
E-mail : pmurali.co@gmail.com  
info@pmurali.com  
Website : www.pmurali.com


To  
The Board of Directors  
VIVIMED LABS LIMITED  
Hyderabad

Limited Review Report for the quarter ended 30<sup>th</sup> September, 2015

1. We have reviewed the accompanying statement of unaudited financial results of M/s. VIVIMED LABS LIMITED for the quarter ended 30<sup>th</sup> September, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of interim financial information performed by the independent auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 10<sup>th</sup> November 2015

For P. Murali & Co.  
Chartered Accountants



*[Signature]*  
Partner